Skip to main content
SpringerLink
Log in

Toxicology and pharmacokinetic study of orally administered 5-iodo-2-pyrimidinone-2′deoxyribose (IPdR) × 28 days in Fischer-344 rats: impact on the initial clinical phase I trial design of IPdR-mediated radiosensitization

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

A toxicology and pharmacokinetic study of orally administered (po) IPdR (5-3iodo-2-pyrimidinone-2′deoxyribose, NSC-726188) was performed in Fischer-344 rats using a once daily (qd) × 28 days dosing schedule as proposed for an initial phase I clinical trial of IPdR as a radiosensitizer.

Methods

For the toxicology assessment, 80 male and female rats (10/sex/dosage group) were randomly assigned to groups receiving either 0, 0.2, 1.0 or 2.0 g kg−1day−1 of po IPdR × 28 days and one-half were observed to day 57 (recovery group). Animals were monitored for clinical signs during and following treatment with full necropsy of one-half of each dosage group at day 29 and 57. For the plasma pharmacokinetic assessment, 40 rats (10/sex/dosage group) were randomly assigned to groups receiving either 0.2 or 1.0 g kg−1day−1 of po IPdR × 28 days with multiple blood samplings on days 1 and 28 and single blood sampling on days 8 and 15.

Results

No drug-related deaths occurred. Higher IPdR doses resulted in transient weight loss and transient decreased hemoglobins but had no effect on white cells or platelets. Complete serum chemistry evaluation showed transient mild decreases in total protein, alkaline phosphatase, and serum globulin. Necropsy evaluation at day 29 showed minimal to mild histopathologic changes in bone marrow, lymph nodes and liver; all reversed by day 59. There were no sex-dependent differences in plasma pharmacokinetics of IPdR noted and the absorption and elimination kinetics of IPdR were found to be linear over the dose range studied.

Conclusions

A once-daily dosing schedule of po IPdR for 28 days with doses up to 2.0 g kg−1day−1 appeared to be well tolerated in Fischer-344 rats. Drug-related weight loss and microscopic changes in bone marrow, lymph nodes and liver were observed. These changes were all reversed by day 57. IPdR disposition was linear over the dose range used. However, based on day 28 kinetics it appears that IPdR elimination is enhanced following repeated administration. These toxicology and pharmacokinetic data were used when considering the design of our initial phase I trial of po IPdR as a clinical radiosensitizer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Berry SE, Kinsella TJ (2001) Targeting DNA mismatch repair for human tumor radiosensitization. Semin Radiat Oncol 11:300–315

    Article  PubMed  CAS  Google Scholar 

  2. Berry SE, Loh T, Yan T, Kinsella TJ (2003) Role of MutSalpha in the recognition of iododeoxyuridine in DNA. Cancer Res 63:5490–5495

    PubMed  CAS  Google Scholar 

  3. Chang AE, Collins JM, Speth PA, Smith R, Rowland JB, Walton L, Begley MG, Glatstein E, Kinsella TJ (1989) A phase I study of intraarterial iododeoxyuridine in patients with colorectal liver metastases. J Clin Oncol 7:662–668

    PubMed  CAS  Google Scholar 

  4. Chang CN, Doong SL, Cheng YC (1992) Conversion of 5-iodo-2-pyrimidinone-2′-deoxyribose to 5-iodo-deoxyuridine by aldehyde oxidase. Implication in hepatotropic drug design. Biochem Pharmacol 43:2269–2273

    Article  PubMed  CAS  Google Scholar 

  5. Efange SM, Alessi EM, Shih HC, Cheng YC, Bardos TJ (1985) Synthesis and biological activities of 2-pyrimidinone nucleosides. 2. 5-Halo-2-pyrimidinone 2′-deoxyribonucleosides. J Med Chem 28:904–910

    Article  PubMed  CAS  Google Scholar 

  6. Kinsella TJ (1996) An approach to the radiosensitization of human tumors. Cancer J Sci Am:184–193

    Google Scholar 

  7. Kinsella TJ, Collins J, Rowland J, Klecker R Jr, Wright D, Katz D, Steinberg SM, Glastein E (1988) Pharmacology and phase I/II study of continuous intravenous infusions of iododeoxyuridine and hyperfractionated radiotherapy in patients with glioblastoma multiforme. J Clin Oncol 6:871–879

    PubMed  CAS  Google Scholar 

  8. Kinsella TJ, Kunugi KA, Vielhuber KA, McCulloch W, Liu SH, Cheng YC (1994) An in vivo comparison of oral 5-iodo-2′-deoxyuridine and 5-iodo-2-pyrimidinone-2′-deoxyribose toxicity, pharmacokinetics, and DNA incorporation in athymic mouse tissues and the human colon cancer xenograft, HCT-116. Cancer Res 54:2695–700

    PubMed  CAS  Google Scholar 

  9. Kinsella TJ, Kunugi KA, Vielhuber KA, Potter DM, Fitzsimmons ME, Collins JM (1998) Preclinical evaluation of 5-iodo-2-pyrimidinone-2′-deoxyribose as a prodrug for 5-iodo-2′-deoxyuridine-mediated radiosensitization in mouse and human tissues. Clin Cancer Res 4:99–109

    PubMed  CAS  Google Scholar 

  10. Kinsella TJ, Schupp JE, Davis TW, Berry SE, Hwang HS, Warren K, Balis F, Barnett J, Sands H (2000) Preclinical study of the systemic toxicity and pharmacokinetics of 5-iodo-2-pyrimidinone-2′-deoxyribose as a radiosensitizing prodrug in two, non-rodent animal species: implications for phase I study design. Clin Cancer Res 6:3670–3679

    PubMed  CAS  Google Scholar 

  11. Kinsella TJ, Vielhuber KA, Kunugi KA, Schupp J, Davis TW, Sands H (2000) Preclinical toxicity and efficacy study of a 14-day schedule of oral 5-iodo-2-pyrimidinone-2′-deoxyribose as a prodrug for 5-iodo-2′-deoxyuridine radiosensitization in U251 human glioblastoma xenografts. Clin Cancer Res 6:1468–1475

    PubMed  CAS  Google Scholar 

  12. Lewandowski GA, Cheng YC (1991) Mechanism and mode of action of 5-iodo-2-pyrimidinone 2′-deoxyribonucleoside, a potent anti-herpes simplex virus compound, in herpes simplex virus-infected cells. Mol Pharmacol 39:27–33

    PubMed  CAS  Google Scholar 

  13. McGinn CJ, Kunugi KA, Tutsch KD, Feierabend C, Alberti D, Lindstrom MJ, Wilding G, Arzoomanian RZ, Kinsella TJ (1996) Leucovorin modulation of 5-iododeoxyuridine radiosensitization: a phase I study. Clin Cancer Res 2:1299–1305

    PubMed  CAS  Google Scholar 

  14. Rooseboom M, Commandeur JN, Vermeulen NP (2004) Enzyme-catalyzed activation of anticancer prodrugs. Pharmacol Rev 56:53–102

    Article  PubMed  CAS  Google Scholar 

  15. Schulz CA, Mehta MP, Badie B, McGinn CJ, Robins HI, Hayes L, Chappell R, Volkman J, Binger K, Arzoomanian R, Simon K, Alberti D, Feierabend C, Tutsch KD, Kunugi KA, Wilding G, Kinsella TJ (2004) Continuous 28-day iododeoxyuridine infusion and hyperfractionated accelerated radiotherapy for malignant glioma: a phase I clinical study. Int J Radiat Oncol Biol Phys 59:1107–1115

    Article  PubMed  CAS  Google Scholar 

  16. Seo Y, Yan T, Schupp JE, Colussi V, Taylor KL, Kinsella TJ (2004) Differential radiosensitization in DNA mismatch repair-proficient and -deficient human colon cancer xenografts with 5-iodo-2-pyrimidinone-2′-deoxyribose. Clin Cancer Res 10:7520–7528

    Article  PubMed  CAS  Google Scholar 

  17. Seo Y, Yan T, Schupp JE Radivoyevitch T, Kinsella TJ (2005) Schedule-dependent drug effects of oral 5-iodo-2-pyrimidinone-2′-deoxyribose as an in vivo radiosensitizer in U251 human glioblastoma xenografts. Clin Cancer Res 11:7499–7505

    Article  PubMed  CAS  Google Scholar 

  18. Sondak VK, Robertson JM, Sussman JJ, Saran PA, Chang AE, Lawrence TS (1998) Preoperative idoxuridine and radiation for large soft tissue sarcomas: clinical results with 5 year follow-up. Ann Surg Oncol 5:106–112

    Article  PubMed  CAS  Google Scholar 

  19. Speth PA, Kinsella TJ, Belanger K, Klecker RW Jr, Smith R, Rowland JB, Collins JM (1988) Fluorodeoxyuridine modulation of the incorporation of iododeoxyuridine into DNA of granulocytes: a phase I and clinical pharmacological study. Cancer Res 48:2933–2937

    PubMed  CAS  Google Scholar 

  20. Sullivan FJ, Herscher LL, Cook JA, Smith J, Steinberg SM, Epstein AH, Oldfield EH, Goffman TE, Kinsella TJ, Mitchell JB, Glatstein E (1994) National Cancer Institute (phase II) study of high-grade glioma treated with accelerated hyperfractionated radiation and iododeoxyuridine: results in anaplastic astrocytoma. Int J Radiat Oncol Biol Phys 30:583–590

    PubMed  CAS  Google Scholar 

  21. Taverna P, Hwang HS, Schupp JE, Radivoyevitch T, Session NN, Reddy G, Zarling DA, Kinsella TJ (2003) Inhibition of base excision repair potentiates iododeoxyuridine-induced cytotoxicity and radiosensitization. Cancer Res 63:838–846

    PubMed  CAS  Google Scholar 

  22. Turner DP, Cortellino S, Schupp JE, Caretti E, Loh T, Kinsella TJ, Bellacosa A (2006) The DNA N-glycosylase MED1 exhibits preference for halogenated pyrimidines and is involved in the cytotoxicity of 5-iododeoxyuridine. Cancer Res 66:7686–7693

    Article  PubMed  CAS  Google Scholar 

  23. Urtasun RC, Cosmatos D, DelRowe J, Kinsella TJ, Lester S, Wasserman T, Fulton DS (1993) Iododeoxyuridine (IUdR) combined with radiation in the treatment of malignant glioma: a comparison of short versus long intravenous dose schedules (RTOG 86–12). Int J Radiat Oncol Biol Phys 27:207–214

    PubMed  CAS  Google Scholar 

  24. Urtasun RC, Kinsella TJ, Farnan N, DelRowe JD, Lester SG, Fulton DS (1996) Survival improvement in anaplastic astrocytoma, combining external radiation with halogenated pyrimidines: final report of RTOG 86–12, phase I–II study. [see comment]. Int J Radiat Oncol Biol Phys 36:1163–1167

    Article  PubMed  CAS  Google Scholar 

  25. Yan T, Seo Y, Schupp JE, Zeng X, Desai AB, Kinsella TJ (2006) Methoxyamine potentiates iododeoxyuridine-induced radiosensitization by altering cell cycle kinetics and enhancing senescence. Mol Cancer Ther 5:893–902

    Article  PubMed  CAS  Google Scholar 

  26. Zarling DAV AK, Kinsella T (2004) New radiosensitizing (RS) regimens, drugs, prodrugs and candidates: Capecitabine, Gemcitabine, Fludarabine, IPdR, Avastin, Veglin, Gleevac, Radvac, Erbitux or Irressa. Clin Adv Hematol Oncol 2:793–805

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, University Hospitals of Cleveland/Case Comprehensive Cancer Center, Cleveland, OH, USA

    Timothy J. Kinsella & Michael T. Kinsella

  2. Chemistry Technical Center, Battelle Memorial Institute, Columbus, OH, USA

    Seongwon Hong, Jerry P. Johnson, Brian Burback & Patricia J. Tosca

  3. Department of Radiation Oncology, University Hospitals Case Medical Center, 11100 Euclid Avenue, Cleveland, OH, 44106-6068, USA

    Timothy J. Kinsella

Authors
  1. Timothy J. Kinsella
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael T. Kinsella
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Seongwon Hong
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jerry P. Johnson
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Brian Burback
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Patricia J. Tosca
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Timothy J. Kinsella.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kinsella, T.J., Kinsella, M.T., Hong, S. et al. Toxicology and pharmacokinetic study of orally administered 5-iodo-2-pyrimidinone-2′deoxyribose (IPdR) × 28 days in Fischer-344 rats: impact on the initial clinical phase I trial design of IPdR-mediated radiosensitization. Cancer Chemother Pharmacol 61, 323–334 (2008). https://doi.org/10.1007/s00280-007-0518-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-007-0518-4

Keywords

Search

Navigation